科创板个股中，截至发稿上涨的共有439只，涨幅在10%以上的共有14只，除南模生物之外，涨停的还 有兴图新科、科思科技等，下跌的有144只，跌幅较大的有科兴制药、奥浦迈、容百科技，分别下跌 9.24%、5.90%、5.70%。 资金面上，南模生物上一交易日主力资金净流出269.58万元，近5日净流出610.19万元。 8月4日盘中科创板股南模生物涨停，截至14:09，股价报43.73元，成交1.12亿元，换手率3.63%，振幅 21.19%。 融资融券数据显示，该股最新（8月1日）两融余额为7593.36万元，其中，融资余额为7593.36万元，较 上一个交易日减少59.85万元，降幅为0.78%；近10日两融余额合计增加1719.55万元，增幅为29.27%， 其间融资余额增长29.27%。（数据宝） （文章来源：证券时报网） ...

Group 1 - The core viewpoint of the article highlights the significant progress made in HIV vaccine research in China, with the completion of the first Phase I clinical trial of a recombinant Tian Tan smallpox vaccine-based HIV vaccine [1] - The innovative approach utilizes the "Tian Tan strain" smallpox virus, previously used to eradicate smallpox, as a vector for the vaccine, demonstrating safety and the ability to elicit an effective immune response [1] - Following this announcement, the A-share market saw a surge in biopharmaceutical stocks, with notable increases including Nanmo Bio and Sairun Bio rising over 14%, and Tiantan Bio hitting the daily limit of 10% [1]

Group 1 - The A-share market saw a surge in biopharmaceutical stocks, with notable increases including Nanmo Bio and Sairun Bio rising over 14%, and Tiantan Bio hitting a 10% limit up [1] - The China CDC and other teams completed the first Phase I clinical trial of a replicative Tian Tan smallpox vaccine-based HIV vaccine, marking a significant advancement in HIV vaccine research in China [1] - The innovative approach utilized the "Tian Tan strain" smallpox virus, previously used to eradicate smallpox, to verify the safety and effective immune response of the vaccine [1]

Core Viewpoint - The announcement details a change in shareholding for Shanghai Nanmo Biological Technology Co., Ltd., indicating an increase in shares held by Shanghai Pudong New Industry Investment Co., Ltd. and its concerted action party, without triggering a mandatory takeover or changing the controlling shareholder [1][2]. Summary by Sections Shareholding Changes - Prior to the change, Shanghai Pudong New Industry held 2,160,000 shares, representing 2.77% of the total share capital, while its concerted action party, Suzhou Haiwang Hezong No.1 Equity Investment Partnership, held 8,679,727 shares, or 11.13%. Together, they held 10,839,727 shares, accounting for 13.90% of the total [1][3]. - On July 16, 2025, Pudong New Industry increased its holdings by 854,800 shares, bringing its total to 3,014,800 shares, or 3.87%. The combined holdings of Pudong New Industry and Haiwang Hezong now total 11,694,527 shares, or 15.00%, reaching a 5% integer multiple [2][3]. Funding Source - The funds used for the share increase by Pudong New Industry were sourced entirely from its own capital, confirming the legality of the funding [4]. Compliance and Regulatory Notes - The share transfer of 8,679,727 shares by Haiwang Hezong is pending compliance confirmation from the Shanghai Stock Exchange and must complete the transfer registration with the China Securities Depository and Clearing Corporation [2][3].

证券代码：688265 证券简称：南模生物 公告编号：2025-044 上海南方模式生物科技股份有限公司 关于股东及其一致行动人权益变动触及 5%整数倍 的提示性公告 信息披露义务人上海浦东新兴产业投资有限公司保证向本公司提供的信息 真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 本次权益变动为上海南方模式生物科技股份有限公司（以下简称"公司" 或"上市公司"）股东增持股份所致，不触及要约收购，不会导致上市公司控股 股东、实际控制人发生变化。 本次权益变动前，上海浦东新兴产业投资有限公司（以下简称"浦东新 产业"或"信息披露义务人"）持有公司股份 2,160,000 股，占公司总股本的 2.77%， 浦东新产业的一致行动人苏州海望合纵一号股权投资合伙企业（有限合伙）（以 下简称"海望合纵"）持有公司股份 8,679,727 股，占公司总股本的 11.13%，浦 东新产业及其一致行动人海望合纵合计持有公司股份 10,839,727 股，占公司总股 本的 13.90%。 海望合纵在本次权益变动前通过协议转让方式受让的 8, ...

上海南方模式生物科技股份有限公司 简式权益变动报告书 上市公司名称：上海南方模式生物科技股份有限公司 股票上市地点：上海证券交易所 股票简称：南模生物 股票代码：688265 信息披露义务人：上海浦东新兴产业投资有限公司 住所：上海市浦东新区周市路 416 号 4 层 信息披露义务人之一致行动人：苏州海望合纵一号股权投资合伙企业（有限 合伙） 住所：江苏省苏州市张家港市杨舍镇暨阳湖金融街 5 幢 204-02 号 权益变动性质：股份增加，信息披露义务人及其一致行动人持股比例合计触 及 5%整数倍 简式权益变动报告书签署日期：2025 年 7 月 16 日 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司收购管理办法》（以下简称"《收购办法》"）、《公开发行证券的公 司信息披露内容与格式准则第 15 号—权益变动报告书》（以下简称"《准则 15 号》"）及相关的法律、法规编写本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 三、依据《证券法》《收购办法》《准则 15 ...

Core Insights - A total of 20 stocks on the STAR Market experienced block trading on July 17, with a cumulative transaction amount of 245 million yuan [1][2]. Group 1: Trading Overview - The total number of block trades was 38, with a cumulative trading volume of 7.45 million shares [1]. - The stock with the highest transaction amount was Nanmo Biology, with a trading volume of 1.56 million shares and a transaction amount of approximately 49.85 million yuan [1]. - Other notable stocks in terms of transaction amounts included Nine Company and Hongquan Wulian, with transaction amounts of 32.40 million yuan and 22.22 million yuan, respectively [1]. Group 2: Price and Performance Analysis - All stocks involved in block trading were sold at a discount, with the highest discount rates observed in Weixin Biology, Haitai Ruisheng, and Guoke Military Industry, with discount rates of 15.49%, 13.79%, and 13.13% respectively [1][2]. - The STAR 50 Index rose by 0.80% on the same day, with 458 stocks (77.76%) in the STAR Market experiencing price increases [1]. - The average increase for stocks involved in block trading was 2.51%, with the highest increases seen in Liyuanheng, Anjisi, and Jiulian Technology, with increases of 8.25%, 7.36%, and 7.05% respectively [1]. Group 3: Institutional Participation - Among the block trades, there were 11 transactions involving institutional buyers or sellers across 8 stocks [2]. - The leading stocks for institutional buying included Anjisi, Jiulian Technology, and Hongquan Wulian, with buying amounts of 10.57 million yuan, 10.52 million yuan, and 8.02 million yuan respectively [2]. - The stocks with the highest net outflows included Nine Company, Weixin Biology, and Anjisi, with net outflows of 33.83 million yuan, 27.47 million yuan, and 13.62 million yuan respectively [2].

Summary of Key Points Core Viewpoint - The financing balance of the Sci-Tech Innovation Board (STAR Market) has increased, indicating a growing interest in investments within this sector, with a total balance of 158.34 billion yuan as of July 1, reflecting a continuous increase over the past seven trading days [1]. Financing Balance - As of July 1, the total financing balance on the STAR Market reached 157.77 billion yuan, an increase of 6.26 million yuan from the previous trading day [1]. - The stock with the highest financing balance is SMIC, with a latest balance of 7.12 billion yuan, followed by Cambrian and Haiguang Information with balances of 4.50 billion yuan and 3.65 billion yuan respectively [1]. - A total of 315 stocks saw an increase in financing balance, while 269 stocks experienced a decrease [1]. - Notable increases in financing balance were observed in Xiangyu Medical (66.24%), Botao Bio (43.29%), and Nanmo Bio (31.08%) [1]. Securities Lending Balance - The total securities lending balance on the STAR Market reached 5.65 billion yuan, with an increase of 8.89 million yuan from the previous trading day [1]. - SMIC also leads in securities lending balance with 20 million yuan, followed by Haiguang Information and Chipone Technology, both at 16 million yuan [2]. - A total of 137 stocks saw an increase in securities lending balance, while 133 stocks experienced a decrease [2]. - Significant increases in securities lending balance were noted for Diao Micro (59.14%), Huahai Qingke (56.71%), and China Shipbuilding Gas (53.60%) [2].

Investment Rating - The report maintains a "Recommended" investment rating for the healthcare sector [7]. Core Insights - The healthcare sector has shown a mixed performance, with the Shenyin Wanguo Pharmaceutical Bio Index rising by 1.60% from June 23 to June 27, 2025, underperforming the CSI 300 Index by 0.35 percentage points [2][12]. - Year-to-date, the pharmaceutical sector has increased by 6.24%, outperforming the CSI 300 Index by 6.57 percentage points, ranking 11th among 31 sectors [2][14]. - As of June 27, 2025, the valuation of the pharmaceutical sector stands at 27.54 times (TTM overall method, excluding negative values), with a premium of 140.94% compared to the CSI 300 [2][17]. Summary by Sections 1. Market Performance - The pharmaceutical sector's performance from June 23 to June 27, 2025, was a 1.60% increase, ranking 23rd among 31 sectors [12]. - The year-to-date performance shows a 6.24% increase, ranking 11th among 31 sectors [14]. 2. Important Events - The National Healthcare Security Administration released the "2025 Basic Medical Insurance Directory and Commercial Insurance Innovative Drug Directory Adjustment Application Guidelines," marking a significant step for commercial health insurance in the multi-level medical security system [4][21]. 3. Industry Perspective - The inclusion of the commercial insurance innovative drug directory indicates an enhanced role for commercial insurance in the multi-level medical security system, providing greater opportunities for the industry [5][22]. - The report expresses optimism for innovative drugs, overseas expansion, and the clearing of procurement in specific segments, suggesting a focus on companies involved in these areas [22].

Group 1 - The core point of the news is the equity change report regarding Shanghai Southern Model Biotechnology Co., Ltd, where Suzhou Haiwang Hezong No. 1 Equity Investment Partnership (Limited Partnership) is increasing its shareholding in the company [1][2] - The report indicates that the equity change is based on the confidence in the company's future development and long-term investment value recognition [9] - The report outlines that the equity change requires compliance confirmation from the Shanghai Stock Exchange and registration procedures with the China Securities Depository and Clearing Corporation [5][38] Group 2 - The information disclosing party, Suzhou Haiwang Hezong, has not held shares in the company prior to this equity change, while its action partner, Shanghai Pudong New Industry Investment Co., Ltd., held 2,160,000 shares, accounting for 2.77% of the total share capital [12][13] - After the equity change, the information disclosing party will hold 8,679,727 shares, representing 11.13% of the total share capital, while the combined holdings with its action partner will total 10,839,727 shares, or 13.90% of the total share capital [12][13] - The share transfer agreement specifies that the shares will be transferred at a price of 27.369 yuan per share, with the total transfer price amounting to approximately 127.27 million yuan [15][56] Group 3 - The report confirms that the equity change does not trigger a mandatory tender offer and will not lead to changes in the controlling shareholder or actual controller of the company [39] - The report also states that the equity change complies with relevant laws and regulations, including the Securities Law and the Acquisition Measures [39] - The information disclosing party has committed to not reduce its holdings in the company for 12 months following the completion of the share transfer [11]